Biocon’s arm bags three year contract from Malaysian Health Ministry

25 Jan 2017 Evaluate

Biocon’s subsidiary - Biocon SDN BHD, Malaysia, has been awarded a three year contract from the Ministry of Health (MoH), Malaysia, for supplying recombinant human insulin (rh-Insulin) formulations manufactured at its large scale biopharmaceutical facility in Johor, Malaysia. Biocon’s rh-Insulin is Malaysia’s first locally manufactured biosimilar biologic product approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia, for commercial sales in the country. This marks the commercialization milestone of Biocon’s first overseas facility in Malaysia.

Biocon SDN. BHD. has been awarded a MYR 300 million (amounting Rs 460 crore) contract to be serviced over a period of three years for supplying rh-Insulin cartridges and re-usable insulin pens under the Malaysian government’s Off-Take Agreement (OTA) initiative, which seeks to encourage local manufacturing of new pharmaceutical products thus lowering the country’s reliance on imports and also enhancing the exports potential. The contract is extendable for additional two years subject to approval by the Government of Malaysia.

Biocon will distribute insulins and insulin delivery devices through CCM Pharmaceuticals, a leading local pharmaceutical player which has an extensive supply chain network to service primary healthcare clinics and hospitals across Malaysia.



Biocon Share Price

389.80 -4.10 (-1.04%)
01-Jan-2026 10:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.05
Dr. Reddys Lab 1251.30
Cipla 1503.05
Zydus Lifesciences 909.40
Lupin 2083.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×